CriticalRequires reviewPossible concern
Recent potassium of 6.2 mmol/L identified in a patient on lisinopril 20 mg daily suggests possible ACE-inhibitor-associated hyperkalemia and may warrant review before this visit.
Rationale
Serum potassium has risen from 4.4 to 6.2 mmol/L over three draws following initiation of lisinopril in a patient with pre-existing stage 3 chronic kidney disease. The FDA label for ACE inhibitors identifies hyperkalemia as a labeled risk, particularly with renal impairment. No subsequent evidence identified that this trend has been addressed in the chart.
Recommended action
Consider repeat basic metabolic panel prior to prescribing, and clinician review of lisinopril dosing in the context of renal function and potassium trend.
Supporting chart evidence
- Potassium (BMP): 6.2 mmol/L on 2026-08-14 (reference range 3.5–5.0 mmol/L)
- Potassium (BMP): 5.1 mmol/L on 2026-07-30 (reference range 3.5–5.0 mmol/L)
- Active medication: Lisinopril 20 mg PO daily, started 2026-07-02
- Active diagnosis: Chronic kidney disease, stage 3 (eGFR 52 mL/min/1.73m²)
Clinician label